00000nam 2200000zi 4500 9.909078 CaOODSP 20221107181823 m o d f cr ||||||||||| 220314e20220407onc ob f000 0 eng d 9780660425481 CaOODSP eng rda CaOODSP n-cn--- H139-39/2022E-PDF Good manufacturing practices inspection policy for drug establishments : POL-0011. [Ottawa] : Health Canada = Santé Canada, April 7, 2022. ©2022 1 online resource (22 pages) text txt rdacontent computer c rdamedia online resource cr rdacarrier Issued also in French under title: Politique d'inspection des bonnes pratiques de fabrication pour les établissements de drogues : POL-0011. "Pub.: 210725." Issued also in HTML format. Includes bibliographical references (pages 20-22). "Establishments need a drug establishment license (DEL) to be authorized to conduct the following licensable activities: fabricate, package/label, test, import, distribute, or wholesale of drugs. Health Canada inspects these sites to verify requirements for good manufacturing practices (GMP) are met before DEL issuance. This helps ensure that safety and quality standards are met by those selling drugs to Canadians"--Purpose, page 4. Pharmaceutical industry Licenses Canada. Pharmaceutical industry Canada Quality control. Drugs Standards Canada. Canada. Health Canada, issuing body. Politique d'inspection des bonnes pratiques de fabrication pour les établissements de drogues : (CaOODSP)9.909079 PDF 930 KB https://publications.gc.ca/collections/collection_2022/sc-hc/H139-39-2022-eng.pdf HTML N/A https://www.canada.ca/en/health-canada/services/drugs-health-products/compliance-enforcement/good-manufacturing-practices/policies-standards/inspection-policy-canadian-drug-establishments.html